Characterization of Skin Th17 Transcriptional Profiles in Psoriatic Patients Under Adalimumab Biotherapy
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 2
- 主要终点
- Analyze modifications of the skin inflammatory
研究概览
简要总结
The expertise in the characterization of transcriptomics profile in lesional psoriatic skin and on the availability of innovative therapy for these patients.The investigators propose to follow the modification of the skin transcriptomics profile in psoriatic patients during successful Adalimumab biotherapy. Skin transcriptomics profiles of normal skin, psoriatic non lesional skin, and psoriatic lesional skin before and after biotherapy will be compared. The investigators will focus on the modification of the cytokine "signature" in these skin lesions and of some markers of keratinocyte inflammation. The modification of the transcriptomics profile induced by the biotherapy will be correlated to the clinical response Psoriasis Area and Severity Index.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults with chronic plaque psoriasis involving at least 10% of body surface area with no previous biotherapy.
- •Adalimumab prescribed in usual practice
排除标准
- •Patients presenting a contraindication to the use of Adalimumab: hypersensibility in Adalimumab or in one of the excipients.
- •Patients presenting an evolutionary tuberculosis or the other severe infections such as sepsis and opportunist infections.
- •Patients with one cardiac insufficiencies moderated in severe.
- •Patients under anakinra or abatacept.
- •Patients with a current participation in another study of clinical research.
研究组 & 干预措施
Adalimumab
干预措施: HUMIRA 40mg (Drug)
结局指标
主要结局
Analyze modifications of the skin inflammatory
时间窗: 1 month
comparaison skin biopsy in non-lesional area between skin biopsy lesional area
次要结局
- skin transcriptomic profile(1 month)